Summary 06-benzylguanine (06-BG) and 3-aminobenzamide (3-AB) inhibit the DNA repair proteins o6_ alkylguanine-DNA alkyltransferase (AGT) and poly(ADP-ribose) polymerase (PARP) respectively. The effect of 06-BG and/or 3-AB on temozolomide and 1,3-bis(2-chloroethyl)-nitrosourea (BCNU) cytotoxicity, was assessed in seven human tumour cell lines: six with an AGT activity of >80 fmol mg-' protein (Mer+) and one with an AGT activity of <3 fmol mg protein (Mer-). Three of the Mer+ cell lines (LS174T, DLD1 and HCT1 16) were considered to exhibit resistance to methylation by a mismatch repair deficiency (MMR-), each being known to exhibit microsatellite instability, and DLD1 and HCT1 16 having well-characterised defects in DNA mismatch binding. Potentiation was defined as the ratio between an IC50 achieved without and with a particular inhibitor treatment. Temozolomide or BCNU cytotoxicity was not potentiated by either inhibitor in the Mer-cell line. Preincubation with 06-BG (100 /M for 1 h) was found to potentiate the cytotoxicity of temozolomide by 1.35-to 1.57-fold in Mer+/MMR+ cells, but had no significant effect in Mer+/MMR-cells.
Temozolomide, a monofunctional methylating imidazotetrazinone, and BCNU, a bifunctional chloroethylnitrosourea, represent two different classes of chemotherapeutic alkylating agent. The anti-tumour activity of both compounds is dependent upon formation of a reactive alkyldiazonium ion (Weinkam and Lin, 1979; Denny et al., 1994) and subsequent alkylation of the accessible nucleophilic atoms of DNA, predominantly N7-guanine, followed by N3-adenine and o6-guanine (Roberts, 1978) . Temozolomide cytotoxicity can largely be accredited to methylation of 06-guanine (Domoradzki et al., 1984; Margison and O'Connor, 1990 ) and N3-adenine (Karran et al., 1982) ; the cytotoxicity/mutagenicity of 06-methylguanine being attributed to the induction of futile cycling in the long patch mismatch repair pathway, which results in prolonged DNA strand interruptions and the inhibition of subsequent replication Karran et al., 1993) . In contrast, the cytotoxicity of BCNU correlates with formation of a l-[N3-deoxycytidyl]-2-[N1-deoxyguanosinyl]-ethane DNA interstrand cross-link (Bodell et al., 1985; Jiang et al., 1989) , which is produced by intramolecular rearrangement of an 06-chloroethylguanine adduct (Tong et al., 1982a) .
Temozolomide has recently demonstrated promising clinical activity in the treatment of glioblastoma and melanoma (Newlands et al., 1992; O'Reilly et al., 1993) , while BCNU is an established agent for the treatment of many malignancies, including glioma and lymphoma (Young et al., 1971; Edwards et al., 1980) . Nevertheless, the activity of DNA-alkylating chemotherapy is frequently compromised by the development of resistance; a phenomenon often related to the DNA repair capacity of the tumour cell (Harris et al., 1983; Ludlum, 1990) . It is therefore possible that the inhibition of one or more DNA-repair processes, by appropriate pharmacological intervention, may circumvent such resistance. This approach has been most widely examined with inhibitors of AGT, a DNA-repair protein responsible for the stoichiometric removal of adducts produced at the 06-position of guanine (Pegg, 1983; Tano et al., 1990) . O6-guanine adduct removal irreversibly inactivates AGT, requiring de novo synthesis of the protein to restore activity (Pegg, 1990) . AGT depletion with the substrate analogue 06-BG has been found to increase the cytotoxicity of both temozolomide and BCNU in vitro (Dolan et al., 1991; Zeller and Magull-Seltenreich, 1995; Wedge et al., 1996a) , and their anti-tumour activity in xenograft experiments Felker et al., 1993; Friedman et al., 1995; Wedge et al., 1996b) . More importantly, the administration of 06-BG has been shown to increase the therapeutic index of BCNU in vivo (Mitchell et al., 1992; Gerson et al., 1993) . However, there may be a need to identify additional DNA-repair mechanisms which can be inhibited to further potentiate DNA-alkylating therapies. This may be particularly relevant to temozolomide, since a methylation-tolerant phenotype can develop from a deficiency in the methyl-directed mismatch repair pathway (Branch et al., 1993; Kat et al., 1993; Karran et al., 1994) , which fails to recognise 06-methylguanine and produce DNA strand breakage. Thus, increasing the retention of o6_ methylguanine by treatment with 06-BG would not be expected to potentiate temozolomide cytotoxicity in a mismatch repair-deficient cell line.
An additional target for manipulation may be PARP, an abundant chromatin-bound enzyme, which has been implicated as having a regulatory role in many cellular processes, including DNA repair (Satoh et al., 1993) . Unmodified PARP binds tightly to DNA strand breaks, but is released following auto-poly(ADP-ribosyl)ation (Satoh and Lindahl, 1992 normal DNA metabolism, or may impede DNA synthesis to prevent replication on a damaged template (Satoh and Lindahl, 1992; Chatterjee and Berger, 1994) . PARP may also have a role in nucleosomal unfolding, since it can ADP ribosylate and electrostatically displace histones (Althaus et al., 1994; Buki et al., 1995) , which would relieve chromatin condensation and facilitate the accessibility of the strand interruption to DNA repair enzymes. Activation of PARP in vitro has been demonstrated following treatment with a number of methylating agents, including dimethyl sulphate (Durkacz et al., 1980) , N-methyl-N'-nitro-N-nitrosoguanidine (Juarez-Salinas et al., 1979) , methyl methanesulphonate (Satoh et al., 1993) , streptozotocin (Whish et al., 1975) and temozolomide (Tisdale, 1985) , while PARP inhibition with 3-AB has been found to enhance methylating cytotoxicity (Durkacz et al., 1980; Biirkle et al., 1987) . PARP activation has also been implicated in response to treatment with a variety of DNA cross-linking agents, which include BCNU (Malapetsa et al., 1995 glutamine (2 mM), penicillin (100 U ml-') and streptomycin (100 Mg ml-'). Cultures were maintained in exponential growth at 37°C in a humidified 5% carbon dioxide incubator.
Assay of AGT activity AGT activity was measured as removal of o6_ [3H]methylguanine from a 3H-methylated DNA substrate, as previously described (Lee et al., 1991; Wedge et al., 1996a) . The AGT activity of an extract was expressed as fmol of
[3H]CH3 transferred from the DNA substrate per mg of protein, using the assay of Bradford et al. (1976) .
Cytotoxicity assay Cytotoxicity was evaluated in 96-well plates as previously described (Wedge et al., 1996a) , using the sulphorhodamine-B (SRB) assay for protein (Skehan et al., 1990) . Conditions for 06-BG incubation were chosen from AGT depletion data. 3-AB incubation conditions were selected from experiments in which 3-AB had been shown to inhibit DNA strand break rejoining and enchance methylating agent cytotoxicity (Durkacz et al., 1980; Burkle et al., 1987) . Both inhibitor treatments (alone and in combination) were determined to be non-growth inhibitory in each cell line. Briefly, cells were plated 24 h before a 1 h preincubation with 0.5% ethanol in DMEM or RPMI-1640, with/without 06-BG (100 /iM).
Medium was then removed from all plates and replaced with that containing either temozolomide (3 h) or BCNU (1 h). Following drug incubation, medium was replenished with 0.2% dimethyl sulphoxide (DMSO) in DMEM or RPMI-1640 with/without 3-AB (2 mM). The medium of all plates was replaced with drug-free medium 48 h later, and plates reincubated for a further 5 days before SRB assay. IC50 values were interpolated by cubic spline regression. Potentiation of temozolomide or BCNU cytotoxicity by 06-BG and/ or 3-AB was taken to be the ratio between the ICso achieved without inhibitor treatment divided by the IC50 achieved with inhibitor treatment.
Statistical analysis and evaluation of combination responses
The significance of a reduction in IC50, obtained by pre-or post-incubation with a DNA repair inhibitor, was analysed using a one-tailed unpaired Student's t-test. The combined effect of 06-BG and 3-AB on temozolomide cytotoxicity was evaluated using the multiple drug effect analysis of Chou and Talalay (1984) , by treating 'temozolomide+O6-BG' and 'temozolomide+3-AB' as two separate 'drugs'. Dose-effect curves were constructed following each individual experiment for each 'drug' and for the combination in a fixed ratio (1: 1) multiple dilution series, using the median effect equation (Chou, 1991) . Computer software (Chou and Chou, 1987) Results 
AGT activity
The AGT activities of HCT-1 16 and DLD-1 were determined to be 87 + 4.7 and 442 + 17 fmol mg-' protein respectively (mean + s.e. from three independent samples). These activities were less than 10% of the control value (i.e. to 5.0+0.7 and 9.9 + 1.4 fmol mg-' protein, respectively), 24 h after incubation with 06-BG (100 /uM, 1 h). Basal AGT activities of U87MG, StML-I la, LS174T, Mawi, and MCF-7 were previously determined to be 2.5, 113, 197, 535 and 721 fmol mg-' protein respectively (Wedge et al., 1996a (Wedge et al., 1996a) , and which demonstrates microsatellite instability characteristic of a mismatch repair deficiency (Shibata et al., 1994) .
Temozolomide Pretreatment with 06-BG significantly reduced the ICs0 of temozolomide in Mer+/MMR+ cell lines (P<0.015, Table I ), and when 3-AB post-treatment was combined with 06-BG pretreatment and temozolomide, it significantly increased the cytotoxicity of the 06-BG and temozolomide combination (P<0.01). Temozolomide cytotoxicity was enhanced to a similar extent by either 06-BG pretreatment (1.35-to 1.57-fold) or 3-AB post-treatment (1.35-to 1.59-fold), and a combination of 06-BG and 3-AB treatment enhanced temozolomide cytotoxicity by 1.97-to 2.16-fold (Figure la) . CI values (mean+s.d.) determined at the IC50 were 0.68+0.10 and 0.79+0.14 for mutually exclusive and non-exclusive combinations respectively, suggesting that the effect of combining an AGT and PARP inhibitor produces an approximately additive (if not slightly synergistic) enhancement of temozolomide cytotoxicity in Mer+/MMR+ cell lines.
In contrast, the IC50 of temozolomide in Mer+/MMRcell lines was not reduced significantly by 06-BG (P>0.05), but very significantly reduced by 3-AB (Table I, (Table II) , thereby potentiating the cytotoxicity of BCNU by 1.94-to 2.57-fold (Figure 2) . Posttreatment with 3-AB produced marginal potentiation (1.19-to 1.35-fold) of BCNU cytotoxicity in Mawi, (Figure 2) . However, the addition of 3-AB to a combination of 06-BG and BCNU did not significantly reduce the IC50 value obtained in any cell line (P> 0.05, Table   II ).
Discussion
While AGT depletion has been widely shown to potentiate the cytotoxicity of both methylating and bifunctional chloroethylating agents, studies investigating PARP inhibition and cytotoxicity have predominantly focused upon methylating agents such as dimethyl sulphate (Durkacz et al., 1980) , N-methyl-N'-nitro-N-nitrosoguanidine (Nduka et al., 1980) and temozolomide (Boulton et al., 1995) . Although it has been suggested that the enhancement of BCNU cytotoxicity by the nucleoside analogue tiazofurin is related to the inhibition of PARP activity , an additional study has indicated that the cytotoxicity of the bifunctional nitrosoureas is unaffected by PARP inhibition (Sebolt-Leopold and Scavone, 1992) .
A wealth of experimental evidence suggests that there is some association between PARP activity and DNA strand breakage (Berger et al., 1979; Durkacz et al., 1980; Shall, 1984; Satoh and Lindahl, 1992) . The mechanism by which 3-AB potentiates cytotoxicity could therefore be related to the alkylation of N7-guanine and N3-adenine by temozolomide (Bull, 1988) and BCNU (Tong et al., 1982b) , which can lead to DNA strand breakage following either enzymatic (Dianov and Lindahl, 1994) or spontaneous (Bailly and Verly, 1988) depurination. These strand breaks are likely to be bound by PARP (Satoh and Lindahl, 1992) . The inhibition of PARP auto(ADP-ribosyl)ation would therefore impede the release of PARP from DNA (and/or nucleosomal unfolding), thereby preventing gap closure and potentiating the cytotoxicity of DNA-alkylating compounds.
A relationship between PARP and DNA strand breakage would support the findings of this study as follows:
(1) Temozolomide cytotoxicity in Mer+/MMR+ cells is dependent upon both the processing of 06-methylguanine by a functional mismatch repair pathway and DNA strand breakage following depurination of 3-methyladenine and 7-methylguanine. These separate cytotoxic events can be independently enhanced by treatment with 06-BG and 3-AB respectively, and an approximately additive response is obtained when the inhibitors are combined (Figure la) . (2) (Milam et al., 1986) . However, that treatment with 3-AB for 48 h did not inhibit the growth of any cell line (data not shown), and that the enhancement of temozolomide and BCNU cytotoxicity by 3-AB was profoundly different in the same cell line (e.g. DLDI, Figure 1 and 2), would suggest that the potentiation observed is unlikely to be related to an effect of 3-AB on DNA synthesis. An effect on ADP(ribose) metabolism is most probable, given that 3-AB (1 mM) can completely inhibit a Potentiation of temozolomide by O6-BG and 3-AB SR Wedge et al 1034 50% reduction in cellular NAD produced by treatment with 2 mM temozolomide (Boulton et al., 1995) . The association between DNA strand breakage and the inhibition of PARP with 3-AB, however, remains controversial (Boulton et al., 1995) , and it is possible that the enhancement of temozolomide cytotoxicity by 3-AB could be related to the inhibition of acceptor protein ADP-(ribosyl)ation, particularly if such proteins regulate cell cycle progression or apoptosis in response to DNA damage (Kastan et al., 1991; Nosseri et al., 1994; Malcomson et al., 1995) . The magnitude by which methylation and chloroethylation cytotoxicity was enhanced by 06-BG did not clearly correlate with AGT activity, although resistance to both agents can be multifactorial and dependent on factors other than at the level of DNA repair. These may include drug-detoxification mechanisms, involving glutathione-S-transferase (Smith et al., 1989; Waxman, 1990) or metallothionine (Kelley et al., 1988) . In addition, the p53 injury-response pathway, which induces G, arrest and/or apoptosis in response to DNA damage (Kastan et al., 1991; Malcomson et al., 1995) , may also contribute to drug resistance following mutational events or overexpression of bcl-2 (Miyashita and Reed, 1992; Fairburn et al., 1994) .
One concern with the use of DNA repair inhibitors is the increase in normal tissue toxicity from DNA-alkylating chemotherapy (Fairburn et al., 1995) , particularly the exacerbation of myelosuppression which is dose limiting for both BCNU and temozolomide. However, this may be clinically managed by appropriate bone marrow and haematopoietic support. The possible enhancement of mutagenesis by AGT depletion, particularly with a methylating agent (Yang et al., 1994) , should be treated with greater trepidation, although the potential short-term therapeutic gain may well outweigh this risk in patients with an otherwise dismal prognosis.
In conclusion, these data indicate that the inhibition of poly(ADP-ribosyl)ation has little effect on the cytotoxicity of BCNU, but that a combination of AGT and PARP inhibitor may have a useful therapuetic role in potentiating temozolomide activity. This study also emphasises that the use of a PARP inhibitor to enhance methylating agent activity will be unaffected by mismatch repair status. Further investigation of the concentration and schedule dependency of 3-AB as a potentiator of temozolomide cytotoxicity may therefore be warranted, although the clinical potential of PARP inhibition will only be realised if more potent and soluble inhibitors become available. 
